Merck said on Friday that its experimental cancer drug helped patients with advanced stomach and esophageal cancers live longer than standard treatment options in a late-stage trial.
Here are some details:
- The trial compared the drug, sacituzumab tirumotecan, also known as sac-TMT, to physician-selected chemotherapy, including trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel
- The trial enrolled 473 patients whose cancer could not be removed by surgery and whose disease had progressed after at least two earlier treatments
- Sac-TMT is an antibody-drug conjugate, a type of targeted cancer therapy designed to deliver cancer-killing drugs directly to tumor cells while minimizing damage to healthy tissue
- Merck said sac-TMT met the trial’s main goal of improving overall survival but did not disclose detailed data, which it plans to present at a future medical meeting
- The study, however, did not meet its secondary goal of delaying cancer progression, as measured by an independent review. Merck said the drug had no new safety concerns
- The results mark another positive late-stage trial for sac-TMT, which Merck licensed from China’s Kelun-Biotech for markets outside Greater China
- Merck is currently testing sac-TMT for multiple cancers, including lung, breast and gastrointestinal tumors
- Merck said the overall survival benefit remained consistent across patient subgroups regardless of TROP2 expression levels, while the drug also showed a nominally improved objective response rate that was not formally tested under the study plan
- TroFuse-015 marks the first time a TROP2-directed antibody-drug conjugate has shown an overall survival benefit in a global Phase 3 trial for advanced gastroesophageal adenocarcinoma, and Merck plans to share the data with health regulators
- The study is the second positive Phase 3 readout from Merck’s TroFuse program, which spans 18 ongoing late-stage trials enrolling more than 15,000 patients across cancers including endometrial, bladder, cervical, and ovarian tumors

